http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2209135-C
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9de26fccd92a5518c57cd8bc47e59949 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16311 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16062 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-92 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 |
| filingDate | 1995-12-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2008-07-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2ba470dcc4c6cc790846cc2e25d64769 |
| publicationDate | 2008-07-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2209135-C |
| titleOfInvention | Human immunodeficiency virus vaccines and therapeutics containing replication-impaired hiv-1 nef-deletion mutants |
| abstract | There is currently no specific immunological treatment utilizing live virus for infection by Human Immunodeficiency Virus (HIV) which is a cause of a clinical syndrome called Acquired Immunodeficiency Syndrome (AIDS). Several prior attempts have been made to develop vaccines to boost the humoral immune response to envelope and gag proteins which have been uniformly unsuccessful because of various factors including cell-to-cell propagation of the HIV and its destruction of the cell mediated immune system of the body by its cytopathic and fatal effect on T HELPER (CD4) cells. The present invention describes a method of creating a recombinant HIV virus clone with its nef gene deleted. The invention further describes a method of creating an injectable suspension of the virus particles and preferred treatment protocol for patients infected with the HIV. A protocol for the prevention of wild-type HIV infection has also been described. It is believed that the preferred embodiment works by eliminating blocking of induction of IL-2 mRNA and IFN.gamma. in lymphoid cells by the nef protein, by developing a cell mediated immune response to HIV via cytotoxic T Lymphocytes (CTL) and by competing with the wild-type HIV for potential hosts and thus increasing the likelihood of exposure of the wild-type HIV to humoral antibodies to gp120, gp4l and gag proteins. |
| priorityDate | 1994-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 484.